Cargando…
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to the tumor microenvironment to provide targets for checkpoint immunotherapy. Inherent in any T cell response to a tumor antigen is the capacity of dendr...
Autor principal: | Bullock, Timothy N. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752810/ https://www.ncbi.nlm.nih.gov/pubmed/34282297 http://dx.doi.org/10.1038/s41423-021-00734-4 |
Ejemplares similares
-
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
por: Bullock, Timothy N. J.
Publicado: (2022) -
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40
por: Khong, Andrea, et al.
Publicado: (2014) -
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
por: Piechutta, Manuel, et al.
Publicado: (2019) -
Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines
por: Ceglia, Valentina, et al.
Publicado: (2022) -
Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease
por: Lim, Yong Taik
Publicado: (2015)